Table 3.
The effect of PDN treatment on the values of clinical measures in MCD patients.
| Before PDN treatment | After PDN treatment | |
|---|---|---|
| Age, years | 48 (38–62) | 48 (38–62) |
| Female/male | 1/3 | 1/3 |
| Urinary protein, g/24 h | 16.31 (6.00–19.22) | 2.78 (1.36–5.27)∗ |
| Serum uric acid, μmol/L | 365 (257–441) | 349 (245–421) |
| Triglycerides, mmol/L | 2.71 (1.55–3.06) | 1.62 (1.21–2.85) |
| Cholesterol, mmol/L | 10.45 (6.20–11.57) | 8.97 (5.67–10.23) |
| eGFR, mL/min/1.73 m2 | 102.36 (94.85–115.3) | 96.43 (74.3–113) |
| Serum albumin, g/L | 15.0 (11–20.9) | 16.72 (15.3–26.4) |
| Microscopic hematuria, rbc/hpf | 3.2 (2.1–9.6) | 1.18 (0.4–2.5) |
| WBC, 109/L | 6.9 (5.32–22.99) | 5.79 (4.87–7.34) |
| Lymphocytes, 109/L | 3.14 (1.74–12.90) | 1.52 (0.67–2.83) |
Data are presented as median (range). *P < 0.05 versus the values before PDN treatment.